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IntroductIon
Innate lymphoid cells (ILCs) patrol epithelial barriers like 
the skin, lungs, and intestine. They provide frontline defense 
against infection and tissue injury but also contribute to 
pathogenic inflammation and thus are viewed as key play-
ers in both protective and deleterious immune responses. 
A growing number of specialized ILC subsets have been 
codified on the basis of functional capabilities and stereo-
typical patterns of cytokine production and transcription 
factor (TF) use (Diefenbach et al., 2014; McKenzie et al., 
2014; Artis and Spits, 2015). NK cells were the first to be 
recognized and are characterized by cytolytic activity, IFN-γ 
production, and the T-box family TF EOM ES. Type 1 ILCs 
(ILC1) also produce IFN-γ but, unlike NK cells, are typically 
not cytolytic and do not express EOM ES. Instead, they are 
specified by a different T-box family member, T-BET, that is 
also expressed by NK cells but not strictly required for their 
cell development (Spits et al., 2016). Type 2 ILCs (ILC2) 
are characterized by production of IL-5 and IL-13 and are 
dependent on GATA-3, along with the retinoid-related or-
phan receptor (ROR) family TF RORα. Type 3 ILCs (ILC3) 
are a heterogeneous group unified by a shared requirement 
for another ROR family member, RORγt. They include 
lymphoid tissue inducer (LTi) cells that produce both IL-17 
and IL-22 and seed lymphoid organs and natural cytotoxic-
ity receptor (NCR) 1–expressing ILC3 that produce IL-22 
but do not participate in organogenesis. Like NK cells and 
ILC1, NCR1+ ILC3 express T-BET and are diminished in 
T-BET–deficient mice, suggesting an ontological relation-
ship and/or lineage plasticity (Sciumé et al., 2012; Klose et 
al., 2013; Rankin et al., 2013).
Although each ILC subset is commonly associated 
with one or two lineage-defining TFs (LDTFs), a simple 
one-to-one instructive model fails to explain the complex-
ity of ILC lineage specification. Instead, this process appears 
to be governed by multifactorial networks with overlap-
ping nodes. Accordingly, genetic ablation of GATA-3 affects 
all ILC subsets, not just ILC2 (Serafini et al., 2014; Yagi et 
al., 2014), and there is a growing list of “multilineage” TFs 
(MLTFs), including ID2, NFIL3, and PLZF, that are required 
for the development of multiple subsets (Constantinides et 
al., 2014; Seillet et al., 2014; Yu et al., 2014; Xu et al., 2015). 
These operate in concert with LDTFs and signal-dependent 
TFs, such as aryl hydrocarbon receptor and NOT CH recep-
tors, which integrate environmental or tissue-derived cues, 
to orchestrate a stepwise differentiation program whereby 
common lymphoid progenitors (CLPs) give rise to a series 
of ILC progenitors that sequentially lose multipotency and, 
ultimately, beget lineage-committed precursors for each 
subset (Diefenbach et al., 2014; Shih et al., 2014; De Obaldia 
and Bhandoola, 2015; Zook and Kee, 2016).
Innate lymphoid cells (ILcs) patrol environmental interfaces to defend against infection and protect barrier integrity. using a 
genetic tuning model, we demonstrate that the signal-dependent transcription factor (tF) StAt5 is critical for accumulation 
of all known ILc subsets in mice and reveal a hierarchy of StAt5 dependency for populating lymphoid and nonlymphoid tissues. 
We apply transcriptome and genomic distribution analyses to define a StAt5 gene signature in natural killer (nK) cells, the 
prototypical ILc subset, and provide a systems-based molecular rationale for its key functions downstream of IL-15. We also 
uncover surprising features of StAt5 behavior, most notably the wholesale redistribution that occurs when nK cells shift from 
tonic signaling to acute cytokine-driven signaling, and genome-wide coordination with t-bet, another key tF in ILc biology. 
collectively, our data position StAt5 as a central node in the tF network that instructs ILc development, homeostasis, and 
function and provide mechanistic insights on how it works at cellular and molecular levels.
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As with adaptive lymphocytes, ILC development and/
or homeostasis is dependent on the common γ chain (γc) 
cytokine receptor and its dedicated tyrosine kinase, JAK3 
(Vonarbourg and Diefenbach, 2012; Serafini et al., 2015; 
Vély et al., 2016). Consequently, ILC subsets can be catego-
rized on the basis of their preferred γc cytokines and core-
ceptors; NK cells and ILC1 require IL-15 and IL-2Rβ, a 
component of the IL-15 receptor, whereas ILC2 and ILC3 
require IL-7 and IL-7R. Because all γc cytokines deploy 
STAT5 as a downstream signal-dependent TF, it is also pre-
sumed to be critical for ILCs. However, until the present 
work, this notion had been validated only for NK cells. 
It has long been known that genetic ablation of STAT5 
results in a profound lack of NK cells, but although this 
dense phenotype conveys vital importance, it precludes 
most functional inquiries (Moriggl et al., 1999; Yao et al., 
2006; Eckelhart et al., 2011). Studies have shown that NK 
cell proliferation and cytotoxicity are reduced in the ab-
sence of Stat5b, one of the two mammalian STAT5 paral-
ogs, but these preceded current understanding of MLTFs 
and LDTFs, and the underlying molecular mechanisms 
were not explored (Imada et al., 1998). Transcriptome-wide 
effects of γc cytokines have also been investigated in NK 
cells (Wang et al., 2015; Gotthardt et al., 2016), but these 
cannot be categorically attributed to STAT5, because γc 
cytokines also engage parallel signaling pathways, including 
mitogen-activated protein kinases and mTOR, that must 
be considered (Huntington et al., 2007; Marçais et al., 2014; 
Mao et al., 2016). In fact, beyond a few emblematic genes, 
such as those encoding BCL family proteins (Sathe et al., 
2014; Shenoy et al., 2014), direct transcriptional targets of 
STAT5 have yet to be cataloged in this or any other ILC 
subset. Thus, the importance of STAT5 for NK cells is not 
in question but its downstream cellular and molecular con-
sequences are loosely defined, and its impact on other ILC 
subsets remains to be determined.
To address these outstanding issues, we used a mouse 
model where STAT5 is reduced but not ablated, thereby 
avoiding the extreme lymphopenia, anemia, and inflamma-
tory disease associated with complete STAT5 deficiency. 
Using this approach, we demonstrate that STAT5 promotes 
accumulation and function of all ILC subsets, as well as var-
ious types of innate-like T cells (ILTCs), and that the degree 
of STAT5 dependency varies according to lineage and tis-
sue of residence. We also applied transcriptome and genomic 
distribution analyses to define a robust STAT5-driven tran-
scriptional signature in NK cells, the prototypical ILC subset, 
and reveal pervasive effects on cellular homeostasis, lineage 
specification, and maturation, as well as striking differences 
between tonic and acute cytokine-driven STAT5 signal-
ing and genome-wide coordination between STAT5 and 
T-BET, an LDTF that is common to the ILC subsets most 
affected by STAT5 deficiency. Collectively, our data position 
STAT5 as a key MLTF involved in ILC development, ho-
meostasis, and function.
reSuLtS
distinct StAt5 thresholds among ILc subsets and precursors
In mammals, STAT5 is encoded by two adjacent genes, 
Stat5a and Stat5b. To avoid the confounding lymphopenia, 
anemia, and inflammatory disease associated with ablation of 
both paralogs, we generated a series of mice with decreasing 
numbers of STAT5 alleles, ranging from four (i.e., two copies 
each of Stat5a and Stat5b) to one (i.e., one copy of either 
Stat5a or Stat5b; Villarino et al., 2016; Fig. S1 A). Strikingly, 
the frequency of splenic NK cells mirrored the total number 
of STAT5 alleles; it was slightly reduced in mice with three 
alleles, lower in those with two, and lower still in those with 
one (Fig. S1, B and C). We also noted that deletion of Stat5b 
alleles had a greater impact than deletion of Stat5a alleles, 
consistent with previous work (Imada et al., 1998).
Contraction of splenic NK cells was most dramatic in 
mice bearing only one STAT5 allele, hereafter referred to 
as one-allele STAT5A- or STAT5B-deficient mice. Thus, 
we focused on these for subsequent experiments. First, 
we quantified NK cells in various tissues (Fig. S2, A–E). 
Compared with WT counterparts, one-allele STAT5A- or 
STAT5B-deficient mice exhibited marked reductions in 
the spleen, liver, and intestinal epithelium but not in the 
bone marrow, suggesting that migration, proliferation and/
or survival defects underlie the phenotypes at peripheral sites 
(Fig. 1 A and Fig. S1 D). ILC1 were also diminished in the liver 
and intestinal epithelium (Fig. 1 A and Fig. S2, C–E), leading 
us to examine the intestinal lamina propia, a tissue known to 
be enriched for all ILC subsets (Fig. S2 F). ILC1 were, again, 
reduced in one-allele STAT5A- or STAT5B-deficient mice, 
as were GATA-3+ ILC2 and RORγt+ ILC3 (Fig. 1 A). Sur-
prisingly, the three constituents of the ILC3 compartment 
were not equally affected. NCR1+ ILC3 were dramatically 
reduced, whereas CD4− and CD4+ LTi cells were not (Fig. 1, 
B and C), although an attendant lack of Peyer’s patches did 
suggest a functional impairment (Fig. 1 D). Like their lam-
ina propia counterparts, epithelial NCR1+ ILC3 were also 
diminished in one-allele STAT5A- or STAT5B-deficient 
mice (Fig. 1 A). Collectively, these data establish that STAT5 
is necessary for accumulation of all ILC subsets, a conclu-
sion strongly supported by the finding that BCL2, a known 
STAT5 target gene that is critical for NK cell homeostasis 
(Viant et al., 2017), was universally depressed (Fig. 1 E). They 
also make clear that STAT5B is the dominant paralog in all 
ILC subsets and reveal a lineage- and tissue-defined hier-
archy of STAT5 dependency; some populations are clearly 
better able to withstand STAT5 depletion than others (e.g., 
liver ILC1 vs. intestinal ILC1).
Similar to ILCs, ILTCs often reside at barrier surfaces 
and do not require antigen-driven differentiation to execute 
effector functions (Cheroutre et al., 2011). In line with prior 
studies implicating STAT5, Jak3, γc, and associated cyto-
kines/receptors (Cao et al., 1995; DiSanto et al., 1995; Park 
et al., 1995; He and Malek, 1996; Maki et al., 1996; Boesteanu 
et al., 1997; Suzuki et al., 1997; Lodolce et al., 1998; Kennedy 
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et al., 2000; Ranson et al., 2003; Hoelbl et al., 2006; Klose et 
al., 2014a; Ettersperger et al., 2016), we found that invariant 
NKT cells in the spleen and liver and γδ T cells, CD4/CD8 
“double-negative” T cells, and CD8αα T cells in the intesti-
nal epithelium were diminished in one-allele STAT5A- or 
STAT5B-deficient mice (Fig. S1 E and Fig. S2, E and G). We 
Figure 1. StAt5 drives accumulation of ILcs at lymphoid and nonlymphoid tissues. (A) Box plot shows total counts for ILC subsets within the in-
dicated tissues. Lamina propia ILC3 refers to all IL-7R+ RORγt+ subsets. Intestinal epithelium ILC3 refers only to the NCR1+ subset. (B) Box plot shows total 
counts for ILC3 subsets in the intestinal lamina propia. NCR1+, NCR1+ ILC3; LTi−, CD4− LTi; LTi+, CD4+ LTi. (C) Flow cytometry contour plots show percentages 
of CD4+ LTi (top left) and NCR1+ ILC3 (bottom right) in lamina propia. (D) Box plot shows total number of macroscopic Peyer’s patches per small intestine. 
(E) Flow cytometry histograms show BCL2 protein levels within the indicated subsets and tissues. (A–E) Data are compiled from or representative of three 
to eight experiments, depending on tissue and subset (n ≥ 3 mice/genotype). *, P < 0.05 (Student’s t test) compared with WT controls. (F) Scatterplot shows 
ILC engraftment after adoptive transfer of mixed bone marrow (STAT5-KO–to-WT starting ratio 5:1) into lymphopenic hosts. Each point represents an in-
dividual donor–host pair. Y axis indicates the observed STAT5-KO to WT ratio for the indicated subsets and tissues. (G) Flow cytometry contour plots show 
representative examples of ILC engraftment in mixed bone marrow chimeras. (F and G) Five or six donor–host pairs were assessed per genotype across two 
experiments. (A–G) See Fig. S2 for detailed flow cytometry gating strategies.
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also noted that, as with ILCs, deletion of STAT5B had a greater 
impact than deletion of STAT5A (Fig. S1 E). Thus, STAT5 is 
necessary for development and/or homeostasis of both ILCs 
and ILTCs, key lymphoid components of innate immunity.
To confirm that the ILC defects seen in one-allele 
STAT5A- or STAT5B-deficient mice are cell intrinsic, we 
transplanted a mix of WT and KO bone marrow progeni-
tors into lymphopenic hosts and compared engraftment in 
the spleen, liver, and intestinal lamina propia. Despite starting 
with a fivefold excess of KO donor cells, WT-derived NK 
cells, ILC1, ILC2, and ILC3 far outpaced their KO counter-
parts, and, echoing the distinction seen in the donor mice, 
one-allele STAT5B-deficient cells were less likely to engraft 
than one-allele STAT5A-deficient cells (Fig.  1. F and G). 
Surprisingly, we found that LTi cells were rarely derived from 
KO donors, indicating that, despite only modest reductions 
in the donor mice, this subset cannot overcome STAT5 defi-
ciency in a competitive setting (Fig. 1 F). Thus, a cell intrin-
sic requirement for STAT5 is evident across all ILC subsets 
and in multiple tissues.
Recent work identified a common progenitor to all 
helper-like ILCs (CHI LP) capable of generating ILC1, ILC2, 
or ILC3 but not NK cells, which are derived from a dedi-
cated NK progenitor (NKp) that branches off at an earlier 
developmental step (Klose et al., 2014b; Yu et al., 2014). Uni-
potent ILC1 and ILC2 progenitors have also been described, 
but an ILC3 equivalent remains at large (Hoyler et al., 2012; 
Constantinides et al., 2015). To determine if the ILC defects 
seen in one-allele STAT5A- and STAT5B-deficient mice are 
due to an early developmental block, we quantified CLPs, 
which can give rise to all lymphoid lineages, CHI LPs and 
lineage-committed NK cell, ILC1 and ILC2 progenitors 
(Fig. S2 H). Both CLPs and CHI LPs were readily detected in 
one-allele STAT5A- and STAT5B-deficient mice, and in fact, 
both were enriched in the latter genotype (Fig. 2, A and B). A 
similar trend was observed for the ILC2 progenitors, suggest-
ing that the loss of this subset in the intestine is due to defects in 
later development, tissue homing, and/or peripheral homeo-
stasis (Fig. 2, A and B). In contrast, NK progenitor (NKp) and 
ILC1p were each diminished in one-allele STAT5B-deficient 
mice (less so in one-allele STAT5A-deficient mice), and the 
residual cells had reduced expression of IL-2Rβ (Fig. 2, A–C). 
Thus, beyond postdevelopmental defects, accumulation of 
NK cells and ILC1 at peripheral sites may be hampered by 
defects in the differentiation and/or fitness of their bone mar-
row progenitors. Considering that multipotent progenitors 
appear largely resistant to STAT5 depletion, we can further 
conclude that its influence becomes most apparent at the lin-
eage-committed precursor stage for these two subsets and at 
a later developmental stage for ILC2.
Impact of StAt5 depletion on ILc tFs and cytokines
Because all ILC subsets were diminished in one-allele 
STAT5A- and STAT5B-deficient mice, we next surveyed 
their respective LDTFs. Expression of T-BET, which is im-
portant for NK cells, ILC1, and NCR1+ ILC3, was notably 
diminished in each of these subsets and across all examined 
tissues (Fig. 3 A). In contrast, EOM ES, which specifies only 
NK cells, was not reduced in the spleen and only marginally 
so in the liver (Fig.  3  B). GATA-3 was diminished in in-
testinal ILC2, and RORγt was slightly reduced in intestinal 
ILC3 (Fig. 3, C and D). Collectively, these data establish that 
STAT5 is required for optimal expression of multiple LDTFs 
involved in ILC specification.
Beyond lineage determination, LDTFs are import-
ant for ILC function. To assess whether reduced LDTF 
expression translates to functional impairment, we mea-
sured effector cytokine production in response to a STAT- 
independent mitogen. Whether assessing IFN-γ in NK 
cells and ILC1, IL-13 in ILC2, or IL-22 in ILC3, the result 
was clear: cytokine production was depressed in one-allele 
STAT5A- and STAT5B-deficient cells compared with 
Figure 2. nK and ILc1 progenitors are diminished in StAt5-deficient 
mice. (A) Box plot shows total counts for common lymphoid progenitors 
(CLPs), common progenitors to all helper-like ILCs (CHI LPs), NK cell pro-
genitors (NKp), ILC1 progenitors (ILC1p) and ILC2 progenitors (ILC2p) in 
the bone marrow (BM). (B) Flow cytometry contour plots show percent-
ages of ILC1p (top left), CHI LPs (bottom left), and ILC2p (bottom right) in 
BM of WT or one-allele STAT5B-deficient mice. (C) Flow cytometry con-
tour plots show percentages of NKp in BM. (A–C) Data are compiled from 
or representative of three experiments (n ≥ 3 mice/genotype). *, P < 0.05 
(Student’s t test) compared with WT controls. See Fig. S2 for detailed flow 
cytometry gating strategies.
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WT controls (Fig.  3 E). Thus, beyond homeostatic defects, 
STAT5-deficient ILCs are functionally compromised.
StAt5 promotes nK cell specification and function
To investigate molecular mechanisms underlying the cellu-
lar phenotypes seen in STAT5-depleted ILCs, we measured 
transcriptomes in NK cells, the prototypical ILC subset. For 
these studies, we sourced NK cells from one-allele STAT5A- 
deficient mice because this genotype presents obvious cellu-
lar phenotypes but retains enough residual cells for ex vivo 
RNA sequencing. As expected, we found that transcription 
of Stat5a was completely extinguished, transcription of Stat5b 
was decreased by half, and transcription of Stat3, the gene 
nearest to the Stat5a/b locus, was unaffected (Fig. S3 A). We 
also confirmed that, despite normal expression of all IL-15 
receptor components, cytokine-driven STAT5 phosphoryla-
tion was depressed (Fig. S3 B). Overall, almost 500 genes were 
differentially expressed relative to WT controls, with com-
parable up- and down-regulated fractions (Fig. S3 C). Gene 
ontology (GO) analysis revealed that transcripts enhanced 
in one-allele STAT5A-deficient NK cells were enriched for 
NF-κB signaling components, particularly genes with TNF 
receptor–like domains, indicating that STAT5 is a negative 
regulator of this pathway and/or its upstream stimuli. On the 
Figure 3. Impact of StAt5 deficiency on ILc-defining transcription factors and cytokines. (A–D) Flow cytometry histograms show T-BET (A), GATA-3 
(B), EOM ES (C), and RORγt (D) protein levels within the indicated subsets and tissues. Data are representative of four to eight experiments, depending on 
tissue and subset (n ≥ 3 mice/genotype). (E) Flow cytometry contour plots show cytokine production by ILCs from the indicated tissues. Data are represen-
tative of two to four experiments, depending on tissue and subset (n ≥ 3 mice/genotype).
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other end of the spectrum, transcripts that were diminished 
in one-allele STAT5A-deficient NK cells were enriched for 
genes associated with cytotoxicity and IFN-γ production, two 
signature NK cell functions, as well as genes bearing C-type 
lectin and Ly49-like domains, two related and functionally 
important classes of molecules that are hallmarks of the NK 
cell lineage (Fig. 4 A).
To establish a role for STAT5 in specifying NK cell lin-
eage identity, we focused on transcripts encoding NK cell 
signature genes, as defined by the Immunological Genome 
Project (Bezman et al., 2012). Remarkably, we observed a col-
lapse of the NK cell signature in one-allele STAT5A-deficient 
NK cells; 52 of 76 genes were reduced compared with WT 
controls (Fig. 4 B). These included various members of the 
killer cell lectin-like receptor subfamily (e.g., Klrk1, Klre1) 
and cytolytic molecules (e.g., Prf1, Gzmb), consistent with 
the appearance of “C-type lectins” and “NK cell cytotoxic-
ity” in our GO analysis (Fig. 4, A and B). However, although 
STAT5 depletion had pervasive effects, certain emblematic 
elements of the NK cell lineage program, including Eomes 
and Nfil3, were not significantly altered, indicating that there 
also are important STAT5-independent components.
Next, we assessed the impact of STAT5 depletion on 
NK cell maturation, the stepwise process by which they be-
come functionally competent. To that end, we curated a list 
of maturation genes and asked whether they were dysregu-
lated in one-allele STAT5A-deficient cells (Vosshenrich and 
Di Santo, 2013). This analysis revealed that genes selectively 
Figure 4. StAt5 promotes nK cell specification and function. (A–C) Transcriptomes were measured in splenic NK cells from WT and one-allele STAT5A- 
deficient mice (Stat5a−/− Stat5b+/−). (A) Differentially expressed genes were segregated on the basis of whether they were enhanced or reduced in 
STAT5-deficient cells, and both groups were subjected to GO analysis. Bar graphs show the top enriched GO, KEGG, and UniProt terms. (B and C) MA plots 
show transcript abundance (x axis, mean RPKM in WT cells) and fold change (y axis, log2 of KO ÷ WT) for genes associated with NK cell identity (B) and NK 
cell maturation (C). (A–C) Two biological replicates were included per genotype. (D) Flow cytometry contour plots show percentages of immature IL7Rhigh 
ITG AMlow (top left) and mature IL7Rlow ITG AMhigh splenic NK cells in WT or STAT5-deficient mice. Data are representative of six experiments. (E and F) Flow 
cytometry contour plot show percentages of immature KLRG1low ITG AMlow (E) or NKG2Dlow (F) splenic NK cells derived from WT or STAT5-deficient donors in 
mixed bone marrow chimera experiments. Five or six donor–host pairs were assessed per genotype across two experiments.
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expressed by mature NK cells, such as Gzma, Itgam, Klrk1, 
and Klrg1, tended to be reduced, whereas those selectively 
expressed by immature NK cells, such as Cd27, Il7r, and Kit, 
tended to be enhanced (Fig. 4 C). We verified several of these, 
including Granzyme A, NKG2D (encoded by Klrk1), and 
KLRG1 (Fig. S3 D), at the protein level and confirmed that 
immature IL7Rhigh ITG AMlow NK cells are enriched in the 
spleens of STAT5-depleted mice (Fig. 4 D). We also confirmed 
that, like the overall frequency of splenic NK cells, there is a 
linear correlation between maturation status and total STAT5 
alleles (Fig. S3 E) and that the maturation defect is cell intrin-
sic; one-allele STAT5A- or STAT5B-deficient donor-derived 
NK cells typically exhibited an immature KLRG1low ITG 
AMlow or NKG2Dlow phenotype in mixed bone marrow chi-
meras (Fig.  4, E and F). Thus, we conclude that STAT5 is 
critical for NK cell maturation and that the relative sparing of 
the NK cells in the bone marrow of STAT5-depleted mice 
reflects a pileup of immature cells that are unable to egress 
from their developmental niche (Figs. S1 D and S3 F).
defining a StAt5 signature in nK cells
STAT family TFs can influence gene expression either di-
rectly or indirectly. The former occurs through physical in-
teractions with proximal (i.e., promoters) and/or distal (i.e., 
enhancers) DNA regulatory elements that enable or disable 
transcription of associated genes; the latter occurs through a 
variety of mechanisms, such as via TF intermediates that are 
themselves direct STAT targets (Villarino et al., 2015). There-
fore, to investigate STAT5 function in ILCs, we produced 
genome-wide DNA binding maps in unstimulated NK cells 
(ex vivo), reflecting tonic signaling, and IL-15–stimulated NK 
cells, reflecting acute cytokine signaling. Surprisingly, we dis-
covered widespread STAT5 occupancy in both settings, with 
similar proportions of gene proximal and distal binding events 
(Fig. 5, A and B). However, peaks found in IL-15–treated cells 
tended to have greater amplitude (i.e., peak height), regardless 
of distance to the nearest gene (Fig.  5 B), and localization 
was distinct; only a quarter of peaks found in IL-15–treated 
samples were also detected in ex vivo samples, and conversely, 
only half of peaks found in ex vivo samples were also detected 
in IL-15–treated samples (Fig. 5 A). Overlapping peaks, ex-
emplified by the IFNg, Il2rb, and Pim1 loci, likely reflect re-
cent exposure to STAT5-activating cytokines by a fraction 
of the ex vivo population because their amplitude typically 
increased after exposure to IL-15 (Fig. 5, C and D). Notably, 
this was often accompanied by acquisition of new binding 
sites, suggesting that some sites can only be detected in the 
context of acute or saturating upstream stimuli (Fig.  5  D). 
Peaks found only in IL-15–treated cells illustrate the rapid 
recruitment of STAT5 to previously unoccupied sites and, 
predictably, were often found near genes whose expression is 
known to be regulated γc cytokines, such as Cish, Tigit, and 
Tnfrsf9 (Fig. 5 E). Peaks found only in ex vivo samples had 
unexpected properties. About half had unique gene associa-
tions, meaning that they were detected near genes that were 
not bound in IL-15–treated cells, such as Irf 7, and about half 
had shared gene associations, meaning that they were detected 
near genes that were also bound in IL-15–treated cells, such 
as Itgam and Itga4 (Fig. 5, C and F). Both scenarios imply 
that STAT5 is redistributed upon exposure to IL-15 and that, 
overall, tonic STAT5 signaling is fundamentally distinct from 
acute STAT5 signaling, likely relating to differences in up-
stream stimuli, dosage and/or kinetics.
To gain further mechanistic insights, we compared 
TF-binding motifs under STAT5 peaks detected in ex vivo 
and/or IL-15–treated NK cells. As expected, canonical 
STAT-binding motifs were highly represented under “IL-15” 
peaks but, surprisingly, not under “ex vivo” peaks (Fig. S4 A). 
Head-to-head analysis yielded similar results: STAT5 was the 
most enriched STAT motif under “IL-15” peaks relative to 
“ex vivo” peaks, but the counter comparison (i.e., “ex vivo” 
vs. “IL-15”) yielded no STAT motif enrichment (Fig.  5 G 
and Table S3). Enrichment of non-STAT motifs was also dis-
tinct. AP-1 components, including JUN-FOS, BATF-JUN, 
and FOSL1, were the top hits under “IL-15” peaks relative to 
“ex vivo” peaks, whereas NRF1, E2F4, and ZBTB33 motifs 
were the top hits in the counter comparison (Fig. 5 H and 
Table S3). Both findings were corroborated by de novo motif 
discovery; STAT and AP-1 were the two most enriched mo-
tifs under “IL-15” peaks but were not evident under “ex vivo” 
peaks (not depicted). “Shared” peaks were also highly enriched 
for STAT5 and AP-1 (relative to “ex vivo” peaks) and exhib-
ited unique properties when compared with “IL-15” peaks, 
such as YY1 motif enrichment (Fig. 5, G and H; Fig. S4 A; 
and Table S3). Thus, STAT5 distribution is mediated largely 
by canonical targeting to STAT motifs in IL-15–treated NK 
cells but not in ex vivo NK cells, which appears to be driven 
by unconventional targeting strategies.
To establish a link between STAT5 binding and gene 
expression, we measured transcriptomic changes in IL-15–
treated NK cells and cross-referenced this data set with our 
STAT5 distribution map, similar to prior work in T cells 
(Lin et al., 2012). Importantly, the majority of the >1,000 
transcripts mobilized in response to IL-15 were negatively 
regulated, indicating that although generally regarded as a 
transcriptional activator, STAT5 often acts as a transcriptional 
repressor in NK cells (Fig. 6 A). We also noted that only ∼20% 
of STAT5-bound genes were transcriptionally responsive and, 
conversely, that only ∼50% of transcriptionally responsive 
genes were STAT5 bound (Fig. 6 A). Building on this latter 
point, we next explored the influence of STAT5-independent 
signaling pathways and/or TFs. To that end, we segregated 
IL-15–responsive genes into STAT5-bound and -unbound 
groups and performed gene set enrichment analysis (GSEA) 
using a collection of “hallmark” gene sets that includes 50 key 
signaling pathways and TFs. As expected, the unbound group 
was positively enriched for downstream targets of mTor 
signaling, a pathway known to mediate important IL-15–
driven functions in NK cells (Marçais et al., 2014; Mao et 
al., 2016), whereas the STAT5-bound group was positively 
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enriched for IL-2/STAT5 signaling (Fig. 6 B and Fig. S4 B). 
We also noted that NF-κB targets were negatively enriched 
in the STAT5-bound group, echoing our GO analysis in 
STAT5-deficient cells (Fig. 4 A), and that Myc target genes 
were positively enriched in both, suggesting that beyond its 
well appreciated role in promoting Myc expression (Pinz et 
al., 2016), STAT5 often colocalizes with this TF (Fig. 6 B and 
Fig. S4 B). Enrichment of Myc and IL-2/STAT5 signaling 
targets within the STAT5-bound group was also confirmed 
with an alternative pathway analysis (Fig. 6 B and Fig. S4 C).
On the basis of our integrated RNA sequencing 
(RNA-seq) and chromatin immunoprecipitation sequenc-
ing (ChIP-seq) analysis, we propose that at least two criteria, 
gene-proximal binding and transcriptional responsiveness to 
Figure 5. Genome-wide distribution of StAt5 in nK cells. (A–F) STAT5 ChIP-seq was performed in ex vivo and IL-15–treated NK cells. (A) Venn diagram 
denotes the total number of unique and overlapping peaks. Percentages denote the fraction of peaks shared between the two conditions. (B) Line graphs 
show the fraction of peaks and amplitude (mean tags per peak) for STAT5 peaks at varying distances from the nearest transcriptional start sites (TSS). 
(C) Histogram shows the relative amplitude (mean tags per base pair) for peaks shared between ex vivo and IL-15–treated NK cells. Bar graph shows per-
centage and absolute number of genes exclusively associated with peaks found in ex vivo or IL-15–treated NK cells. Denominator is all genes assigned to 
the 3,332 or 9,410 peaks described in A. (D–F) Genome browser tracks show STAT5 peaks at selected loci exhibiting overlapping (D), “IL-15 only” (E), or “ex 
vivo only” (F) distributions. (G and H) Weblogos depict the top enriched STAT (G) and non-STAT (H) transcription factor–binding motifs under STAT5 peaks 
from ex vivo and/or IL-15–treated NK cells. Shown are corrected p-values and rank of each motif among all database hits. (A–H) Data are presented from 
one of two biological replicates per condition.
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Figure 6. transcriptional activity and cooperativity of StAt5 downstream of IL-15. Transcriptomes were compared between ex vivo and IL-15–
treated NK cells. Differentially expressed genes were then segregated on the basis of whether or not STAT5-binding sites were detected near transcriptional 
start sites in IL-15–treated NK cells. (A) Left donut plot reports the total number of positively or negatively regulated genes from among all STAT5-bound 
genes. Right donut plot reports the total number of STAT5-bound, positively or negatively regulated genes from among all IL-15–regulated genes. (B) GSEA 
was applied to STAT5-bound and STAT5-unbound, IL-15–regulated genes. Bar graphs show hallmark pathway genes sets that were reduced or enhanced by 
IL-15. FDR, false discovery rate; NES, normalized enrichment score. (C) Left heat map shows the fold change in RPKM (log2 of IL-15–treated ÷ untreated) for 
all IL-15/STAT5 signature genes across three biological replicates. Right heat maps shows the RPKM fold change for a selection of signature genes and peak 
amplitude for the highest associated STAT5 peaks in untreated or IL-15–treated cells. (D) Left pie chart shows the number of IL-15/STAT5 signature genes 
among NK cell signature genes. Right pie chart shows the number of genes with nearby STAT5 peaks among NK cell signature genes that are not included 
in the STAT5 signature. (E) Transcriptomes were measured in IL-15–treated WT and T-BET–deficient NK cells and GSEA performed using STAT5 signature or 
IL-15–regulated, STAT5-unbound gene sets. Circle plot relays whether gene sets were enhanced or reduced in T-BET–deficient NK cells (y axis), along with 
gene set count (element size; number shown) and false discovery rate (y axis). Two biological replicates were included per genotype. (F) Genome browser 
tracks show STAT5 and T-BET distributions at selected loci. (G) Histogram shows the position and amplitude of T-BET-binding sites relative to STAT5-binding 
sites in ex vivo NK cells.
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upstream stimuli, should be met to classify a gene as a di-
rect STAT5 target. Following this principle, we devised two 
STAT5 gene signatures for NK cells, one with 513 elements 
and a more compact 73-element version devised using more 
stringent criteria for both STAT5 binding and transcriptional 
responsiveness (Fig.  6  C and Table S4). Importantly, one 
quarter of NK cell signature genes are represented, includ-
ing Gzmb, Klrk1, and Itgam, indicating that NK cell lineage 
identity is, in large part, defined by the IL-15–STAT5 axis 
(Fig. 6 D). We also found that at least two elements, Tnfrsf9 
and Il2ra, are regulated by γc cytokines in other ILC subsets, 
suggesting the signatures may be applicable to other lineages 
and/or upstream stimuli (Fig. S4 D).
coordination between StAt5 and t-bet
During our ILC survey, we noted that the subsets most af-
fected by STAT5 deficiency, NK cells, ILC1, and NCR1+ 
ILC3, all express T-bet. To further probe the relationship be-
tween these two TFs, we first confirmed that T-bet-deficient 
mice phenocopy STAT5-deficient mice in terms of ac-
cumulation and maturation of splenic NK cells (Fig. S5, A 
and B). Importantly, this phenocopy was evident despite 
normal IL-2Rβ expression and IL-15–driven STAT5 phos-
phorylation in T-bet-deficient NK cells (Fig. S5, C and D). 
Next, we measured transcriptomes in IL-15–treated WT 
and T-bet-deficient NK cells and applied GSEA using our 
513 and 73 element STAT5 signatures. Both gene sets were 
highly enriched in WT NK cells, indicating that T-bet typi-
cally promotes expression of genes that are directly regulated 
by STAT5 (Fig. 6 E and Fig. S5 E). In contrast, complemen-
tary “unbound” gene sets were enriched in T-bet–deficient 
NK cells, indicating that T-bet typically inhibits expression 
of IL-15–regulated genes that are not direct STAT5 targets 
(Fig.  6  E and Fig. S5 E). We also compared genome-wide 
distributions and found widespread overlap between STAT5 
and T-bet; 63% of STAT5 peaks had overlapping T-bet peaks, 
with salient examples found near genes whose expression was 
diminished in one-allele STAT5A-deficient NK cells, includ-
ing Tbx21 (which encodes T-bet) and Gzmb (Fig. 6, F and 
G). Collectively these data establish that STAT5 and T-bet 
regulate many of the same genes and suggest a collaborative 
relationship in NK cells.
dIScuSSIon
The intimate relationship between γc cytokines and ILCs first 
became apparent >30 yr ago when it was discovered that IL-2 
promotes NK cell cytotoxicity (Rosenberg and Lotze, 1986). 
It is now well established that γc cytokines profoundly influ-
ence NK cell biology, but the molecular basis for their varied 
effects remains loosely defined. A major impediment has been 
the fact that deletion of STAT5, the principal signaling moiety 
downstream of γc and its coreceptors, is incompatible with NK 
cell viability (Moriggl et al., 1999; Yao et al., 2006; Eckelhart 
et al., 2011). One approach for circumventing this issue has 
been to “rescue” STAT5-deficient NK cells through ectopic 
expression of the anti-apoptotic protein BCL2 (Minagawa et 
al., 2002; Gotthardt et al., 2016). These studies conclude that 
several key NK cell processes are subject to STAT5 but, inevita-
bly, are confounded by STAT5-independent effects of the Bcl2 
transgene (Minagawa et al., 2002; Gotthardt et al., 2016). To 
overcome this caveat, we generated mice that retain one of four 
Stat5 alleles, thereby restricting availability of STAT5 in NK 
cells, and all other ILC subsets, while avoiding the severe hema-
topoietic and immunological abnormalities seen in complete 
STAT5 KOs or BCL2-transgenic mice (Egle et al., 2004; Yao 
et al., 2006). By applying cytometry- and transcriptome-based 
phenotyping, we demonstrate that STAT5 is not only critical 
for NK cell homeostasis and function, as predicted by prior 
work in mice lacking upstream cytokines or receptors (Cao et 
al., 1995; Cooper et al., 2002; Colucci et al., 2003; Koka et al., 
2003; Ranson et al., 2003; Vosshenrich et al., 2005; Imamura et 
al., 2014), but also for lineage specification and maturation. We 
also expanded its purview to all known ILC subsets and vari-
ous types of ILTCs, in line with previous studies on upstream 
regulators, including Jak3, γc, IL-2Rβ, IL-7/IL-7R, and IL-15/
IL-15R (Satoh-Takayama et al., 2008, 2010; Moro et al., 2010; 
Price et al., 2010; Vonarbourg et al., 2010; Hoyler et al., 2012; 
Daussy et al., 2014; Klose et al., 2014b; Merzoug et al., 2014; 
Vély et al., 2016; Robinette et al., 2017), and establish STAT5B 
as the dominant paralog in ILCs and ILTCs. Because the tran-
scriptional output of Stat5b is greater than that of Stat5a in 
NK cells (Fig. S3 A), we interpret that the apparent dominance 
of STAT5B in this subset, and perhaps others, is due to lower 
STAT5 protein levels in one-allele STAT5B-deficient cells 
rather than widespread functional disparity between STAT5 
paralogs, as shown for helper T cells (Villarino et al., 2016).
A unique benefit of our genetic model is that by retain-
ing one allele of Stat5a or Stat5b, we were able to compare 
two different levels of STAT5 depletion, the former more 
profound than the later. This enabled us to uncover a lin-
eage- and tissue-defined hierarchy of STAT5 dependency 
among ILC and ILTC subsets; with splenic and intestinal NK 
cells, intestinal ILC1, and intestinal NCR1+ ILC3 at the top 
of the scale, followed by intestinal ILC2, splenic NKT cells, 
liver NK cells, intestinal CD8αα T cells, and intestinal CD4/
CD8 double-negative T cells, and ending with intestinal γδ 
T cells, liver ILC1, liver NKT cells, intestinal LTi cells, and 
bone marrow NK cells, which appear least sensitive to re-
duced STAT5 availability. Among ILCs, STAT5 dependency 
broadly correlates with each subset’s preferred γc cytokines—
IL-15–sensitive NK, ILC1, and NCR1+ ILC3 are more af-
fected than ILC2 and LTi (Fig. S5 F)—and with steady-state 
proliferation; the percentage of Ki67+ cells is greater for lam-
ina propia ILC1 (7.9 ± 2.0) and NCR1+ ILC3 (13.8 ± 2.9) 
than LTi (1.9 ± 1.1). Both of these concepts, along with the 
vital importance of the γc-STAT5 axis, are well illustrated by 
recent work showing that IL-15 can foster ILC development 
and function in the absence of IL-7R (Robinette et al., 2017).
Depletion of ILCs in one-allele STAT5A- and 
STAT5B-deficient mice does not appear to be due to an early 
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developmental block, as CLPs and CHI LPs were present in 
both genotypes, consistent with similar findings in γc- and 
IL-7–deficient mice (Klose et al., 2014b). ILC2 progenitors 
were also present, but NK cell and ILC1 progenitors were 
sharply diminished, indicating that they are more sensitive 
to reduced STAT5 availability (Fig. S5 F). These latter find-
ings contrast with prior work in γc- and IL-7R–deficient 
mice, so we interpret that (a) ILC2 progenitors can make due 
with limited amounts of STAT5, and (b) alternative stimuli 
promote STAT5-dependent NKp development in the ab-
sence of γc or IL-7R (Vosshenrich et al., 2005; Hoyler et 
al., 2012; Robinette et al., 2017). Notwithstanding, our data 
point toward postdevelopmental defects as a major disrup-
tive force in one-allele STAT5A- and STAT5B-deficient and 
suggest a central role for STAT5 in promoting ILC fitness 
at various tissues, specifically via its ability to induce tran-
scription of anti-apoptotic proteins such as BCL2. We also 
demonstrate that residual ILCs from one-allele STAT5A- and 
STAT5B-deficient mice are functionally compromised, indi-
cating that, beyond homeostatic concerns, STAT5 participates 
in effector programing of various subsets.
Beyond affirming the importance of STAT5, our work 
provides valuable insights on how it operates at molecular 
and genomic levels. First, we discovered that genome-wide 
STAT5 distribution is distinct for ex vivo and IL-15–treated 
NK cells, which implies that its steady-state behavior, reflect-
ing tonic signaling and/or the activity of “unphosphory-
lated” STAT5, is fundamentally different from acute behavior 
downstream of γc cytokines. Importantly, STAT-binding mo-
tifs were not enriched under peaks found in ex vivo NK cells, 
suggesting alternative targeting mechanisms but were highly 
enriched under peaks found in IL-15–treated NK cells, con-
sistent with the long-standing idea that γc cytokines induce 
rapid recruitment of STAT5 to canonical binding sites. We 
also cross-referenced our IL-15–driven STAT5 distribution 
map with complementary transcriptome analyses to devise a 
robust STAT5-driven transcriptional signature and thus pro-
vide a strictly defined molecular rationale for its varied activ-
ities in NK cells. This strategy also allowed us to distinguish 
between direct STAT5 targets and alternative signaling path-
ways or TFs downstream of IL-15, such as mTor and Myc, 
thereby confirming the influence of the latter.
Like STAT5, T-bet is required for accumulation of NK 
cells, ILC1, and NCR1+ ILC3 (Townsend et al., 2004; Gordon 
et al., 2012; Sciumé et al., 2012; Klose et al., 2013; Rankin et 
al., 2013; Daussy et al., 2014). Strikingly, we found that these 
subsets were the most diminished in STAT5-depleted mice 
and that, in all cases, T-bet protein levels were lower in the 
residual cells. Considering that multiple studies (including the 
present work) have shown that STAT5 directly engages the 
Tbx21 locus (Liao et al., 2011; Villarino et al., 2016), we can 
infer that STAT5 is an important upstream regulator of T-bet 
in ILCs. However, we did not detect an increase in T-bet ex-
pression when WT NK cells or ILC1 were acutely exposed 
to γc cytokines, likely because T-bet expression was already 
saturated because of in vivo exposure to STAT5 stimuli and/
or other instructive signals (unpublished data). Notwithstand-
ing, our data suggest a collaborative relationship in NK cells, 
the prototypical ILC subset. We demonstrate that STAT5 and 
T-bet colocalize throughout the genome and that STAT5 sig-
nature genes are depressed in the absence of T-bet, suggesting 
that it may promote STAT5 activity at direct target genes. 
Considering that multiple T-bet+ innate and innate-like 
lymphocytes were diminished in one-allele STAT5A- and 
STAT5B-deficient mice, including ILC1, NCR1+ ILC3, 
NKT cells, γδ T cells, and CD8αα T cells (Townsend et al., 
2004; Klose et al., 2014a; Reis et al., 2014), we propose that 
this relationship is important beyond NK cells.
Collectively, our data position STAT5 as a key MLTF 
involved in ILC specification, homeostasis, and function. 
Consequently, we can infer that ILC defects contribute to the 
panoply of symptoms seen in patients with loss-of-function 
STAT5B mutations, which notably exhibit a lack of circu-
lating NK cells and barrier surface pathologies, particularly 
in the skin and lungs (Kanai et al., 2012). Thus, we believe 
that our findings have clinical relevance not only in terms 
of understanding STAT5 function under healthy and disease 
states but also as a warning for potential side effects that may 
accompany therapeutic intervention of this pathway.
MAterIALS And MethodS
experimental animals
STAT5-deficient mice were generated as described (Villarino 
et al., 2016). In brief, mice lacking the entire STAT5 locus 
(Stat5a/b+/−) were crossed with mice lacking one allele of 
Stat5a (Stat5a+/− Stat5b+/+) or Stat5b (Stat5a+/+ Stat5b+/−) 
to produce eight allele combinations (Fig. S1 A). We refer to 
each genotype according to the number of Stat5 alleles that 
are retained. For example, one-allele Stat5a-deficient mice 
lack both Stat5a alleles but retain one Stat5b alleles (Stat5a−/− 
Stat5b+/+), whereas one-allele Stat5b-deficient mice lack both 
Stat5b alleles but retain one Stat5a allele (Stat5a+/− Stat5b−/−). 
Tbx21−/− and WT C57BL/6 mice were purchased from The 
Jackson Laboratory. Animals were housed and handled in ac-
cordance with National Institutes of Health (NIH) guide-
lines and all experiments approved by the National Institute 
of Arthritis and Musculoskeletal and Skin Diseases (NIA MS) 
Animal Care and Use Committee.
cell purifications
Tissues were dissected from 8–16-wk-old mice and single- 
cell suspensions made using the following methodologies. 
Spleens were mechanically dissociated and red blood cells 
depleted by hypotonic lysis (Gibco/Life Technologies). Liv-
ers were depleted of circulating lymphocytes by flushing 
5 ml PBS through hepatic portal veins, then all lobes were 
mechanically dissociated and lymphocytes enriched using 
Lymphocyte Separation Medium (Corning). Bone marrow 
was flushed from rear femurs and red blood cells depleted 
by hypotonic lysis. Lamina propia lymphocytes and intraep-
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ithelial lymphocytes were isolated from large intestines. In 
brief, fat deposits and Peyer’s patches were removed, luminal 
contents flushed and tissues sectioned into 1-cm segments. 
These were then bathed in HBSS containing 5 mM EDTA 
and 10 mM Hepes, mechanically sheared, incubated in HBSS 
containing 0.5 mg/ml DNase I and 0.25 mg/ml Liberase TL 
(Roche), and strained (100-µm filter). Lamina propia lym-
phocytes were enriched using 80%/40% Percoll gradient (GE 
Healthcare). All cell cultures were performed in RPMI-1640 
medium supplemented with 10% fetal calf serum, 1% sodium 
pyruvate, 1% nonessential amino acids, 10 mM Hepes, 0.1% 
β-mercaptoethanol, 100 U/ml penicillin, and 100 mg/ml 
streptomycin (Life Technologies).
Flow cytometry
Cells were stained either directly ex vivo or after in vitro 
culture with IL-15 (20–50 ng/ml) using fluorochrome-la-
beled anti-mouse antibodies recognizing the following pro-
teins: BCL-2, CD3ε, CD4, CD8α, CD8β, CD11b (ITG AM), 
CD19, CD25 (IL-2Rα), CD27, CD45.1, CD45.2, CD45R 
(B220), CD49b (DX5), CD90.1, CD90.2, CD117 (c-Kit), 
CD122 (IL-2Rβ), CD127 (IL-7R), CD132 (γc), CD135 
(FLT3), CD137 (TNF RSF9 or 4-1BB), CD215 (IL-15R), 
CD253 (TRA IL), CD278 (ICOS), Eomes, GATA-3, Gran-
zyme A, IFN-γ, Intergin α4β7 (LPAM), IL-13, IL-22, KLRG1, 
NCR1 (NKp46), NK1.1, NKG2D (KLRK1), RORγt, Sca1 
(Ly-6A/E), STAT5 (pTyr-694), T-BET, TCRγ, and/or TIG 
IT (all from eBioscience, BD Biosciences, or BioLegend). 
For detection of intracellular proteins, cells were fixed and 
permeabilized with a combination of Cytofix/Cytoperm 
(BD Biosciences) and 100% methanol. For cytokine produc-
tion, single-cell suspensions were stimulated with Phorbol 
12-myristate 13-acetate and ionomycin for 5–6  h (50 and 
500 ng/ml, respectively) including Brefeldin A (10 µg/ml) for 
the final 3 h (all from Sigma-Aldrich). For bone marrow pro-
genitor studies, cells were stained with biotinylated Lineage 
Cell Depletion kit antibody cocktail (containing anti-mouse 
CD5, CD45R [B220], CD11b, Ly-6G/C [Gr-1], Ly-6B.2, 
and Ter-119; Miltenyi Biotec) and biotinylated anti-NK1.1 
and anti-NKp46 in conjunction with fluorochrome-labeled 
streptavidin. Phycoerythrin-labeled, αGalCer-loaded CD1d 
tetramers were purchased from ProImmune. Data were col-
lected on a FACSverse cytometer (BD Biosciences) and ana-
lyzed using FlowJo (FlowJo LLC). Compiled cytometry data 
are presented as box plots in which horizontal lines indicate 
the mean of all replicates and whiskers indicate minimum and 
maximum values. See Fig. S2 for detailed gating strategies.
Bone marrow chimeras
Lineage-positive cells were depleted from WT (CD45.1 or 
CD90.1 congenic), Stat5a−/− Stat5b+/− or Stat5a−/− Stat5b+/− 
bone marrow by negative selection using the Lineage Cell 
Depletion kit supplemented with biotinylated anti-NKp46 
and anti-CD25 (Miltenyi Biotec). These were washed and re-
suspended in PBS, then WT and KO cells were mixed (WT-
to-KO ratio 1:5) and intravenously transferred to sex-matched 
γc−/− Rag2−/− hosts (500 µl total). Engraftment was measured 
8–12 wk later in spleen, liver, and intestinal lamina propia.
rnA sequencing and transcriptome analysis
Cell sorting was used to isolate CD19− CD3ε− NCR1+ 
CD49b+ NK cells from spleens of WT, Stat5a−/− Stat5b+/−, 
and Tbx21−/− mice (>98% purity). Cells were processed 
either directly ex vivo or after in vitro culture with 20 ng/ml 
mouse IL-15 (eBioscience) for 12 (Stat5a−/− Stat5b+/− ex-
periments) or 48 h (Tbx21−/− experiments). Equal numbers 
of cells (0.5–5 × 105) were used per genotype/condition for 
each experiment. These were lysed in Trizol reagent, and 
total RNA was isolated by phenol-chloroform extraction 
with GlycoBlue as a coprecipitant (7–15 µg per sample; Life 
Technologies). Single-end libraries were prepared using the 
TruSeq RNA Sample Preparation kit v.2 and sequenced 
using a HiSeq 2500 instrument (Illumina). 50-bp reads (>20 
million per sample) were mapped onto mouse genome build 
mm9 using TopHat and further processed using Cufflinks. All 
data sets are normalized on the basis of reads per kilobase of 
transcript per million mapped reads (RPKM) and purged of 
micro-RNAs, small nucleolar RNAs, and small Cajal body–
specific RNAs. When multiple transcripts were detected for a 
single gene, only the most abundant (i.e., highest mean RPKM 
across all genotypes and conditions) was considered for down-
stream analyses. To minimize “fold change artifacts” caused by 
low-abundance transcripts, a small offset (equal to the sec-
ond quartile of all data points) was added to RPKM values, 
and transcripts with RPKM values of <1 in all genotypes/
conditions were excluded. Transcript variance was calculated 
using Edge-R. Transcripts were classified as differentially ex-
pressed genes (DEGs) if they exhibited >1.5-fold change and 
significant pairwise variance (P < 0.05) compared with ex 
vivo WT controls. Two or three biological replicates were se-
quenced per genotype or condition (Table S1). Volcano plots, 
bar graphs, and MA plots were generated with DataGraph 
(Visual Data Tools). NK cell signature and NK cell maturation 
gene sets used for MA plots are described in Table S4.
DAV ID bioinformatics resources were used for GO 
analysis of DEG from Stat5a−/− Stat5b+/− NK cells (National 
Institute of Allergy and Infectious Diseases). Only lower level 
GO terms (GO:00) with more than threefold enrichment 
and a <10% false discovery rate were considered, and only 
the highest scoring among redundant terms were graphed. 
Disease-associated KEGG terms were excluded. Ingenuity 
Pathway Analysis was used to predict “upstream regulators” 
in STAT5-bound or -unbound DEGs from WT NK cells 
treated with IL-15 (Ingenuity Systems).
GSEA was performed as previously described (Sub-
ramanian et al., 2005). For IL-15 experiments, RPKMs for 
STAT5-bound or -unbound DEGs were run against GSEA 
hallmark gene sets (Liberzon et al., 2015). All gene sets with 
normalized enrichment scores greater than 2 or less than 
−2 in the STAT5-bound group are shown, and a matching 
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number and pattern are presented for the STAT5-unbound 
data set (Fig. 6 B). Enrichment curves and member ranks are 
shown in Fig. S4 B. For Tbx21−/− NK cell experiments and 
unabridged RNA-seq data sets were used with the STAT5 
signature gene sets detailed in Table S4. A circle plot was 
generated with DataGraph (Fig. 6 G). All RNA-seq data are 
available from the NCBI Gene Expression Omnibus under 
accession no. GSE100674.
chromatin immunoprecipitation and dnA sequencing
107 NK cells were purified from spleens of WT mice by mag-
netic bead separation (90% purity; negative selection kit by 
Miltenyi Biotec) and fixed with 1% formaldehyde either di-
rectly ex vivo or after treatment with mouse IL-15 (2 h, 20 
ng/ml). Cells were then lysed and sonicated before immu-
noprecipitation with rabbit anti-mouse pan-STAT5 antibody 
(ab7969; Abcam). Recovered STAT5-bound DNA fragments, 
along with unprecipitated “input controls,” were blunt-end 
ligated to adaptors and single-end libraries prepared using the 
NEBNext ChIP-Seq Library Prep for Illumina kit (New En-
gland Biolabs). Sequencing was performed on a HiSeq 2500 
instrument (50 cycles; Illumina), and Bowtie was used to map 
>10 million nonredundant 50-bp reads to mouse genome 
build mm9. Peaks with more than twofold enrichment over 
background, p-values < 0.00001, and false discovery rate < 5% 
were called with MACS 1.4.2 using input controls as back-
ground reference. Two biological replicates were sequenced 
per condition (Table S2). bamCorrelate from deepTools v.1.5 
was used to calculate Spearman’s rank correlation coefficients 
as a measure of interreplicate variability (ex vivo r = 0.8737, 
IL-15 r = 0.8737, P < 2.2 × 10−16 for both). Downstream 
analyses were performed separately; data shown are from the 
second replicate. ChIP-seq data for T-BET in ex vivo NK 
cells have been published (Shih et al., 2016).
The IL-15/STAT5 signature (513 elements) includes 
genes that (a) are STAT5-bound based on ChIP-seq from 
IL-15–treated NK cells (peak detected within gene body 
or ± 50 kb from transcriptional start site) and (b) are tran-
scriptionally regulated by IL-15 on the basis of RNA-seq 
comparison of ex vivo and IL-15–treated NK cells (more 
than twofold change in RPKM; P < 0.05). The compact 
IL-15/STAT5 signature (73 elements) includes genes that 
(a) exhibit high amplitude STAT5 peaks (tag count for at 
least one gene-associated peak is within the top 25% of all 
peaks) and (b) exhibit more than threefold change in RPKM 
downstream of IL-15 (P < 0.05). Only genes with mean 
RPKM > 2 in either ex vivo or IL-15–treated NK cells 
are included (Table S4).
Direct comparison of peak distribution across experi-
mental groups was done with PAP ST and annotated to the 
nearest gene using HOM ER. Peaks are assigned to genes if 
they occur within introns, exons, and/or <50 kb from tran-
scriptional start sites. Peak distribution was further analyzed, 
and histograms were generated using ChAsE. Known and 
de novo TF motif enrichment analysis was performed using 
the AME and DRE ME tools of the MEME suite, focusing 
on JAS PAR database outputs. Line graphs, donut plots, and 
pie charts were generated using DataGraph. Heat maps were 
generated using Multi Experiment Viewer (J. Craig Venter 
Institute). Genome browser tracks are displayed with the In-
tegrative Genomics Viewer (Broad Institute). All ChIP-seq 
data are available from the NCBI Gene Expression Omnibus 
under accession no. GSE100674.
Statistics
Unpaired homoscedastic Student’s t test was used to quan-
tify statistical deviation between experiential groups. Aster-
isks denote significant differences (P < 0.05) compared with 
WT controls.
online supplemental material
Fig. S1 details the mouse models used in this study and shows 
the frequency of splenic NK cells in all genotypes. Fig. S2 
shows flow cytometry gating strategies for NK cells, ILC 
subsets, ILTCs, and ILC precursors. Fig. S3 shows transcrip-
tome and flow cytometry data comparing WT and one-allele 
STAT5A-deficient NK cells. Fig. S4 shows enrichment of 
STAT-binding motifs under STAT5 ChIP-seq peaks, GSEA 
enrichment plots for hallmark genes, upstream regulator 
analysis for STAT5-bound and -unbound DEGs, and flow 
cytometry data for STAT5 signature genes in various ILC 
subsets. Fig. S5 shows flow cytometry–based phenotyping 
of Tbx21−/− NK cells, GSEA enrichment plots for STAT5 
signature genes in WT and Tbx21−/− NK cells, and a car-
toon illustrating the hierarchy of STAT5 dependency among 
ILC subsets and precursors. Table S1 is a spreadsheet con-
taining RPKM measurements, fold change calculations, and 
p-values for RNA-seq experiments. Table S2 is a spreadsheet 
containing annotated STAT5 ChIP-seq data. Table S3 is a 
spreadsheet containing enrichment ranks and p-values for 
TF-binding motifs found under STAT5 peaks. Table S4 is a 
spreadsheet defining the STAT5 gene signature in NK cells 
and all gene sets used for transcriptome analysis. Tables S1–S4 
are provided as Excel files.
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